Effects on cell viability and cell cycle of apigenin on BCPAP cell line of thyroid cancer

Authors

SUN Zhen, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China
ZHENG Jie, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China
ZHANG Li, Key Laboratory of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, Jiangsu 214063, China
ZHAO Junjie, Munitions Representative Bureau Munitions and Fuel Commission General Logistics Department, Beijing 100071, China
YU Huixin, Key Laboratory of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, Jiangsu 214063, China

Abstract

To investigate the effects on cell viability and cell cycle of apigenin on BCPAP cell line, the MTT assay was used to detect the growth inhibition rates of BCPAP cells at 24 h which cultured with apigenin in different concentrations, and of BCPAP cells at 24, 48, 72 h which cultured with 12.5, 25, 50 μmol/L apigenin as well. The bright field images of cell morphology were analyzed. The effects were evaluated of different concentration of apigenin on the morphology of BCPAP cells, and the inhibition of cell growth. The cell cycle distribution was measured by flow cytometry. The different concentrations (12.5～100 μmol/L) of apigenin had cytotoxicity on BCPAP cells, which were clearly dose-and time-dependent. The IC₅₀ of 24 h is 40.65 μmol/L. There are significant effects of apigenin on the morphological changes of BCPAP cells, and the high concentration of apigenin strongly inhibited BCPAP cell growth in numbers. Cells were treated with apigenin which had significant effects on cell cycle of BCPAP cell, and induced apoptosis. Apigenin had significant cytotoxicity and inhibition of cell viability on thyroid cancer BCPAP cells. One of the mechanisms may be that it might make significant G2/M phase arrest and induced apoptosis, and a decrease of cell viability, then the cell number was declined.

Publication Date

6-28-2015

First Page

3

Last Page

7

DOI

10.13652/j.issn.1003-5788.2015.03.001

Recommended Citation

Zhen, SUN; Jie, ZHENG; Li, ZHANG; Junjie, ZHAO; and Huixin, YU (2015) "Effects on cell viability and cell cycle of apigenin on BCPAP cell line of thyroid cancer," Food and Machinery: Vol. 31: Iss. 3, Article 1.
DOI: 10.13652/j.issn.1003-5788.2015.03.001
Available at: https://www.ifoodmm.cn/journal/vol31/iss3/1

References

[1] Kilfoy Briseis A, Zheng Tong-zhang, Holford Theodore R, et al. International patterns and trends in thyroid cancer incidence［J］. Cancer Causes Control, 2009, 20(5): 525～531.
[2] Harach H, Franssila, Wasenius. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland［J］. A Systematic Autopsy Study. Cancer, 1985, 56(3): 531～538.
[3] Londero S C, Krogdahl A K, Bastholt L. Papillary thyroid carcinoma in Denmark 1996~2008: An investigation of changes in incidence［J］. Cancer Epidemiology, 2013, 37(1): 1～6.
[4] Ersen A, Durak M G, Canda T, et al. Warthin-like papillary carcinoma of the thyroid: a case series and review of the literature［J］. Turk Patoloji Derg, 2013, 29(2): 150～155.
[5] Brito J P, Hay I D, Morris J C. Low risk papillary thyroid cancer［J］. British Medical Journal, 2014, 348(3 045): 1～10.
[6] Al-Shakhrah I A. Radioprotection using iodine-131 for thyroid cancer and hyper-thyroidism: a review［J］. Clinical Journal of Oncology Nursing, 2008, 12(6): 905～912.
[7] Choudhury D, Ganguli A, Dastidar D G, et al. Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulin［J］. Biochimie, 2013, 95(6): 1 297～1 309.
[8] Tong Xin, Pelling J. Targeting the PI3K/AKT/mTOR axis by apigenin for cancer prevention［J］. Anticancer Agents Med. Chem., 2013, 13(7): 971～978.
[9] Balasubramanian S, Eckert R L. Keratinocyte proliferation, differentiation, and apoptosis-differential mechanisms of regulation by curcumin, EGCG and apigenin［J］. Toxicol Appl Pharmacol, 2007, 224(3): 214～219.
[10] Batra P, Sharma A K. Anti-cancer potential of flavonoids: recent trends and future perspectives［J］. 3 Biotech, 2013, 3(6): 439～459.
[11] Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: Progress, potential and promise (Review) ［J］. International Journal of Oncology, 2007, 30(1): 233～245.
[12] Akhavan M, Jahangiri S, Shafaghat A. Studies on the antioxidant and antimicrobial activity and flavonoid derivatives from the fruit of Trigonosciadium brachytaenium (Boiss.) Alava［J］. Industrial Crops and Products, 2015, 63(1): 114～118.
[13] Singh R P, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention［J］. Endocr Relat Cancer, 2006, 13(3): 751～778.
[14] Meeran S M, Katiyar S K. Cell cycle control as a basis for cancer chemoprevention through dietary agents［J］. NIH Public Access, 2008, 13(1): 2 191～2 202.
[15] Wu Guo-yi, Xu Li-nan, Lin Nan, et al. UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines［J］. BMC Cancer, 2013, 13(167): 1～9.
[16] Park K I, Park H S, Nagappan A, et al. Induction of the cell cycle arrest and apoptosis by flavonoids isolated from Korean Citrus aurantium L. in non-small-cell lung cancer cells［J］. Food Chemistry, 2012, 135(4): 2 728～2 735.
[17] Chang Chi-chang, Hung Chao-ming, Yang Yun-ru, et al. Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells［J］. Journal of Ovarian Research, 2013, 6(41): 1～7.